|Publication number||US3862189 A|
|Publication date||Jan 21, 1975|
|Filing date||Aug 14, 1973|
|Priority date||Aug 14, 1973|
|Publication number||US 3862189 A, US 3862189A, US-A-3862189, US3862189 A, US3862189A|
|Inventors||Charles F Schwender|
|Original Assignee||Warner Lambert Co|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Referenced by (38), Classifications (11)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent n91 Schwender Jan. 21, 1975 1 ARALKYL-SUBSTITUTED PURINES AND PYRIMIDINES AS ANTIANGINAL BRONCHODILATOR AGENTS  Inventor: Charles F. Schwender, Lebanon,
 Assignee: Warner-Lambert Company, Morris Plains, NJ.
 Filed: Aug. 14, 1973  Appl. No.: 388,290
 US. Cl 260/252, 260/253, 260/254, 260/256.4 N, 424/253  Int. Cl C07d 57/38  Field of Search 260/252, 253, 254
 References Cited UNITED STATES PATENTS 3,412,093 11/1968 Podesva et al 260/252 Primary Examiner-Donald G; Daus Assistant Examiner-Anne Marie T. Tighe Attorney, Agent, or Firm-Albert H. Graddis; Frank S. Chow  ABSTRACT The present invention relates to compounds of for mula 1:
These compounds are useful as antianginal or bronchial dilator agents.
20 Claims, No Drawings ARALKYL-SUBSTITUTED PURIN AND PYRIMIDINES AS ANTIANGINAL BRONCHODILATOR AGENTS The present invention is concerned with novel compounds and. more particularly, the present invention is concerned with aralkyLsubstituted purines and pyrimidines having structural formula l:
wherein R is hydroxy, methoxy, mercapto, hydrazino, substituted hydrazino, chloro, amino, alkylamino, dialkylamino, hydroxyalkylamino, aralkylamino or substituted aralkylamino and R is phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety and at least two alkoxy, alkyl, halogen, hydroxy, nitro, amino, substituted amino, aminomethyl, acylamino, carboxy, carboxyalkyl or hydroxymethyl groups in the benzene ring or naphthylalkyl, tetrahydronaphthylalkyl, quinolylalkyl, tetrahydroquinolylalkyl or isoquinolylalkyl, each having 1 to 3 carbon atoms in the alkyl moiety and pharmaceutically acceptable acid addition salts thereof.
In addition, esters or amides of the above compounds utilizing alkanoyl or aralkanoyl, such as acetyl, propionyl, benzoyl, succinoyl and the like, and the pharmaceutieally acceptable acid addition salts are also within the scope of this invention.
In the above definitions for R the term alkyl means an aliphatic hydrocarbon having I to 6 carbon atoms, for example, methyl, propyl, isopropyl, isobutyl and the like. The term aryl denotes an aromatic hydrocarbon having 6 to l4 carbon atoms, for example, phenyl, naphthyl, anthryl and the like. The term aralkyl designates a combination of the hereinbefore defined alkyl and aryl groups. Substituted hydrazino denotes hydrazino substituted on either nitrogen atom or both nitrogen atoms by one or more alkyl or aryl groups.
In the above definitions for R the term alkyl stands for an aliphatic hydrocarbon of l to 6 carbon atoms, unless otherwise specified, and applies to the alkyl residues of the alkoxy and acyl moieties. Substituted amino includes within its scope amino groups substituted by alkyl and aryl groups defined in the preceding paragraph. Halogen encompasses all of the halo groups, chloro, bromo, iodo and fluoro.
Among the preferred compounds of this invention are those purine derivatives wherein R is chloro, amino, hydroxy, hydrazino, n-propylamino or 2- hydroxyethylamino and R is dimethoxybenzyl and R, is amino and R is dichlorobenzyl, 3,4-dimethylbenzyl.
The compounds of this invention exhibit a unique mode ofbiological action in that they produce selective dilation of certain coronary arteries causing a redistribution of blood flow towards isehemic areas of the heart enhancing perfusion and reducing anoxia which cause anginal pains. This biological activity is demonstrated in accordance with the procedure described in J. Pharmacol. Exp. Ther., l76,l84 (1971). Only nitroglycerin and some B-adrenergic blockers have been demonstrated to similarly redistribute blood flow to ischemic areas by large coronary artery dilation. See Eur. J. Pharmacol., I6, 271 (1971 The compounds of this invention offer an advantageous treatment of angina without interference with adrenergic control of the heart or without resorting to the use of nitrates.
Existing coronary vasodilators such as dipyridamole and chromonar dilate smaller vessels increasing coronary blood flow without redistributing flow to needed ischemic areas. In severe ischemia, dipyridamole actually induced anginal attacks in man since it diverted blood flow away from ischemic areas through its dilator action on smaller coronary vessels. See Ann. Rep. Med. Chem, 7, 69 (i972).
Experimentally, this blood flow redistribution is demonstrable in a dog by measuring changes in resistance to blood flow of larger coronary arteries (RL) relative to small vessel physical resistance to flow (RT), using the protocol described in J. Pharmacol. Exp. Ther.. 176, 184(1971).
Generally, the compounds of this invention at a dose of about 1-10 mg/kg were observed to effect a drop in the RLzRT ratio. Known coronary vasodilators such as dipyridamole and chromonar caused an increased RLzRT ratio reflecting a redistribution of blood flow away from ischemic tissues.
The compounds of this invention, particularly the preferred species, are indicated in the management of angina pectoris. A usual dose of l-lO mg/kg by injection or orally two or three times daily is suggested to prevent anginal attack. These compounds can be ad- ,ministered by combining with excipients such as lactose or water for injection.
In addition to the antianginal effects described above, the compounds of this invention were also observed to protect guinea pigs from histamine-induced bronchial spasm. Thus tested in accordance with the procedure described in J. Pharmacol. Exp. Ther., 90, 254 (1947) at a dose of 1-50 mg/kg intraperitoneally, they were effective to protect the guinea pigs against bronchial spasms which had been induced by the administration of one mg of histamine. At this dosage level, a mild cardiotonic effect was also observed. Hence, the compounds of this invention are also useful in the treatment of bronchial spasms such as in bronchial asthma. Generally'speaking, a dose of 1-50 mg/kg administered orally or by intramuscular injection is suggested.
According to the present invention, the above compounds are prepared by processes as illustrated in the following reaction scheme:
Method A N'H; Method B N/ k I m I N RZNHZ Nl/ \NHRZ (ECO) sCH l N II or R (MeO) CH III 2 Method C Method D Nucleophile N I to I 2 Referring now to the reaction scheme. in Method A 5-amino-4,6-dichloropyrimidine is condensed with a substituted amine in butanol and triethylamine. The resultant substituted amino pyrimidine II is cyclizcd with triethyl or trimethyl orthoformate to the 6- chloropurine derivative III as in Method B. Treating said 6-chloropurine derivative with ammonia as brought out in Method C, or an appropriate nucleophile as in Method D, gives the (a-substituted purine derivative l.
The starting material for the first process, S-amino- 4.6-dichloropyrimidine is available from commercial chemical suppliers such Krishell Laboratories, Inc. The amino compounds utilized in Method A, triethyland trimethyl orthoformate of Method B and the nucleophiles of Method D are available from the Aldrich Chemical Company or readily preparedby methods well known to those skilled in the art.
In addition, treatment of adenine with a substituted benzyl or aralkyl halide in the presence of a base such as sodium hydride gives the desired 9-substituted adenine directly. This reaction is illustrated by the following reaction scheme:
NH: Method E )I 51:? R x \N a, 2 R
Adenine, the starting material for the second process is commercially available from the Aldrich Chemical Company as are the requisite aralkyl halides. R- X.
The following experiments are general procedures for the preparation of the compounds olthis invention: all temperatures are in degrees Centigrade.
TABLE I Recrystallization R Formula Analysis* moC- Solvent Method Preparation Ci H ',ClN, 0; citNcl 188-191 MeOH/H=O A ocii ocii 8}: C H CINaO= cuacl 133-135 neon/1120 A OCH, 0011, v cuiiucmt CHNCl 219-223 MeOH/H;O A
C: 0 nac m ciiucl 197-19s.5 MOE/H 0 A *Cenpountls reported analyzed with in :OJrZ of theory.
percent); P l 21f' REFERENCES l. M. M. Winhury, B. B. Howe, H. R. Weiss. J. Pharmacol. Exp. Then, I76, 184 (1971).
2. M. M. Winbury. H. R. Weiss and B. B. Howe. Eur. J. PharmaeoL, 16. 271 (1971).
3. H. R. Weiss and M. M. Winhury, Fed. Proc., 30 (2) 631 (1971). 4. O. Mantcro and F. Conti, Circulatory Drugs, A. Bcrtelli. ed. pp
| 18-123. NorthHolland, Amsterdam, The Netherlands, 1969.
5. C. F. Schwcnder. Antianginal Agents, Ann. Rep. Med. Chem, 7. 69. R. V. Heinzelmann, ed. Academic Press. New York, 1972.
6. O. H. Siegmuhd, H. R. Granger and A. M. Lands. J. Pharmacol. Exp. Ther., 90. 254 (1947).
METHOD A crystallized by trituration with water. The crude yellow' solid was recrystallized from methanol-water to give 1.61 g (90.1 percent), mp 185-l88, of crystalline product. The analytical sample was obtained by recrystallization from methanol-water; yield, 1.36 g (76.9
METHOD B 6-Chloro-9-(3.4-dimethoxybenzyl)purine. To a suspension of 15.6 g (52.8 mmols) of 5-amino-4-chloro-6- (3.4-dimethoxybenzylamino)-pyrimidine in 100 ml of triethyl orthoformate was added 149 mg 1.36 mmols) oi ethanesulfonic acid and the resulting mixture was heated at 80 for min. Upon cooling and addition of hexane to the reaction mixture, a yellow precipitate formed which was collected by filtration; yield, 15.4 g (95.6 percent) mp l '59l63. Recrystallization from EtOH H O gave the analytical sample;-yield 13.2 g (82.2 percent) mp l60l64.
METHOD C METHOD D 6-Propylamino-9-veratrylpurine. A reaction mixture containing 5.14 g (16.8 mmol) of 6-chloro-9- veratrylpurine. 7.0 ml (84.9 mmol) of propylamine and 60 ml of EtOH was refluxed for 2.5 hrs. Evaporation of the reaction mixture gave a residual solid which was recrystallized from acetone togive the crude product; yield 4.78 g (87.0 percent) mp 1l.7-120. Further re crystallizations of the crude white material from acetone gave the analytical materialymp 122-l25.
METHOD E 9-(3,4-Dimethylbenzyl)adenine (W10,813). An ice cold suspension containing adenine (10.0 g, 74 mmol), 3.74 g (89.0 mmol) of NaH (57 percent suspension in oil) and 120 ml of'DMF was allowed to reach RT and stirred for one additional hourf3,4-Dimethylbenzyl chloride 13.7g 89 mmol) was'added to the reaction I amino and R is l-naphthylmethyl.
crystallization from methanol; mp 21 1-213.
Anal. Calcd for C,,H,,-,N C, 66.38; H, 5.97; N, 27.65. Found: C, 66.38; H, 6.l0; N, 27.80.
' I claim:
1. A compound of the formula 1:
wherein R, is, chlori fl hydi'oiy mercapto, alkoxy of l to 6 carbon atoms, hydrazino, amino, amino substituted by one or two alkyl groups each of l to 6 carbon atoms, amino substituted by l-naphthylmethyl or benzyl, or hydroxy-alkylamino of l to 6 carbon atoms and R 15 l-naphthylmethyl; phenylmethyl. and phenylethyl substituted on the phenyl group by two or three alkoxy groups of l to 6 carbon atoms, 2 or 3 alkyl groupsot 1 to 6 carbon atoms, or two chloros and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1 in which R, is methoxy and R is 3,4-dimethoxybenzyl.
3. A compound according to claim 1 in which R, is mercapto and R is 3,4-dimethoxybenzyl.
4. A compound according to claim 1 in which R, is l-naphthylmethylamino and R is 3,4- dimethoxybenzyl.
5. A compound according to claim 1 in which R, is amino and R is 3,4-dimethoxybenzyl 6. A compound according to claim 1 in which R, is hydroxy and R is 3,4-dimeth'oxybenzyl.
7. A compound according to claim 1 in which R, is benzylamino'and R is 3,4-dimethoxybenzyl.
8. A compound according to claim I in which R, is 2-hydroxyethylamino and R is 3.4-dimethoxybenzyl.
9. A compound according to claim 1 in which R, is chloro and R is 3,4-dimethoxyhenzyl.
10. A compound according to claim 1 in which'R, is hydrazino and R is 3,4-dimethoxybenzyl.
ll. A compound according to claim 1 in which R, is l-propylamino and R is 3,4-dimethoxybenzyl.
12. A compound according to claim 1 in which R, is chloro and R is 2-(3,4-dimethoxyphenyl)ethyl.
13. A compoundaccording to claim 1' in which R, is amino and R is 2-( 3,4-dimethoxyphenyl)ethyl.
14. A compound according to claim 1 in which R, is chloro and R is l-naphthylmethyl'.
l5. A compound according to claim 1 in which R, is
. l6. A compound according to claim 1 in which R, is propylamino and R is l-naphthylmethyl.
17. A compound according to claim 1 in which R, is l-hydroxyethylamino and R is l-naphthylmethyl.
18. A compound according to claim 1 in which R, is amino and R is 3,4-dimethylbenzyl..
19. A compound according to claim 1 in which R, is chloro and R is 3,4-dichlorobenzyl.
20. A compound according to claim 1 in which R, is
r, amino and R is 3,4-dichlorobenzyl.-
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3412093 *||Dec 15, 1966||Nov 19, 1968||Delmar Chem||New adenine derivatives and method for their preparation|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3996361 *||Dec 10, 1974||Dec 7, 1976||Boehringer Mannheim G.M.B.H.||N6 -Substituted-9-[3-(4-phenyl-piperazino)-propyl]-adenines|
|US4221909 *||Sep 15, 1978||Sep 9, 1980||Sloan-Kettering Institute For Cancer Research||P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines|
|US4221910 *||Sep 15, 1978||Sep 9, 1980||Newport Pharmaceuticals International, Inc.||9-(Hydroxy alkyl)purines|
|US4241063 *||Aug 6, 1979||Dec 23, 1980||Bristol-Myers Company||Purine derivatives and their use as bronchodilators|
|US4269839 *||Sep 13, 1979||May 26, 1981||Bristol-Myers Company||Alkylthio-adenines used as bronchodilators|
|US4278675 *||Sep 13, 1979||Jul 14, 1981||Bristol-Myers Company||Bronchodilating process|
|US4340726 *||Mar 14, 1980||Jul 20, 1982||Newport Pharmaceuticals International, Inc.||Esters|
|US4407802 *||Sep 28, 1981||Oct 4, 1983||Merck & Co., Inc.||6-Amidino-9-substituted benzyl purines|
|US4634706 *||Oct 25, 1984||Jan 6, 1987||Sankyo Company Limited||Griseolic acid derivatives, and their use as enzyme inhibitors|
|US4666914 *||May 13, 1985||May 19, 1987||Schering Corporation||Anti-inflammatory and anti-allergic substituted-2,3-dihydro-6-(hydroxy)pyrimido[2,1-f]-purine-4,8(1H,9H)-diones|
|US4816458 *||Dec 19, 1986||Mar 28, 1989||Schering Corporation||Method of treating hyperploliferative skin disease with substituted-2,3-dihydro-6-substituted -pyrimido[2,1]-purine-4,8(1H,9H)diones|
|US5017578 *||Jun 9, 1989||May 21, 1991||Hoechst-Roussel Pharmaceuticals Inc.||N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents|
|US5155098 *||May 6, 1991||Oct 13, 1992||Hoechst-Roussel Pharmaceuticals Inc.||N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them|
|US5256650 *||Sep 30, 1992||Oct 26, 1993||Merrell Dow Pharmaceuticals Inc.||Selective adenosine receptor agents|
|US5329007 *||Jul 29, 1993||Jul 12, 1994||Merrell Dow Pharmaceuticals Inc.||Selective adenosine receptor agents|
|US5391739 *||Mar 8, 1994||Feb 21, 1995||Merrell Dow Pharmaceuticals Inc.||Selective adenosine receptor agents|
|US6316456 *||Nov 29, 1996||Nov 13, 2001||Centre National De La Recherche Scientifique||Purine derivatives having, in particular, antiproliferative properties, and their biological uses|
|US6660745||May 9, 2000||Dec 9, 2003||Mitsubishi Chemical Corporation||Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof|
|US6734187||Jul 23, 2002||May 11, 2004||Mitsubishi Chemical Corporation||Purine derivatives and medicaments comprising the same as active ingredient|
|US6919455||Aug 1, 2003||Jul 19, 2005||Mitsubishi Chemical Corporation||Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof|
|US8163762||Apr 24, 2012||Centre National De La Recherche Scientifique (Cnrs)||Purine derivatives having, in particular, anti-proliferative properties, and their biological uses|
|US8680108||Dec 17, 2010||Mar 25, 2014||Incyte Corporation||Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors|
|US8759359||Dec 17, 2010||Jun 24, 2014||Incyte Corporation||Substituted heteroaryl fused derivatives as PI3K inhibitors|
|US8940752||Jun 28, 2010||Jan 27, 2015||Incyte Corporation||Pyrimidinones as PI3K inhibitors|
|US9062055||Jun 21, 2011||Jun 23, 2015||Incyte Corporation||Fused pyrrole derivatives as PI3K inhibitors|
|US9096600||Dec 19, 2011||Aug 4, 2015||Incyte Corporation||N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors|
|US9108984||Mar 13, 2012||Aug 18, 2015||Incyte Corporation||Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors|
|US9126948||Mar 23, 2012||Sep 8, 2015||Incyte Holdings Corporation||Pyrimidine-4,6-diamine derivatives as PI3K inhibitors|
|US9193721||Apr 13, 2011||Nov 24, 2015||Incyte Holdings Corporation||Fused derivatives as PI3Kδ inhibitors|
|US9199982||Aug 31, 2012||Dec 1, 2015||Incyte Holdings Corporation||Heterocyclylamines as PI3K inhibitors|
|US9309251||Apr 1, 2013||Apr 12, 2016||Incyte Holdings Corporation||Bicyclic azaheterocyclobenzylamines as PI3K inhibitors|
|US20040077665 *||Aug 1, 2003||Apr 22, 2004||Mitsubishi Chemical Corporation||Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof|
|US20100273802 *||Oct 28, 2010||Centre National De La Recherche Scientifigue (C.N.R.S.)||New purine derivatives having, in particular, anti-proliferative properties, and their biological uses|
|US20110183985 *||Jul 28, 2011||Yun-Long Li||Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors|
|US20110190319 *||Aug 4, 2011||Combs Andrew P||Substituted heteroaryl fused derivatives as pi3k inhibitors|
|EP0157637A2 *||Apr 2, 1985||Oct 9, 1985||The Wellcome Foundation Limited||Heterocyclic compounds|
|EP0390112A2 *||Mar 28, 1990||Oct 3, 1990||Merrell Pharmaceuticals Inc.||Selective adenosine receptor agents|
|WO1999024432A1 *||Nov 12, 1998||May 20, 1999||Mitsubishi Chemical Corporation||Purine derivatives and medicine containing the same as the active ingredient|
|U.S. Classification||544/264, 544/277, 544/265, 514/826|
|International Classification||C07D239/48, C07D473/00|
|Cooperative Classification||C07D473/00, Y10S514/826, C07D239/48|
|European Classification||C07D239/48, C07D473/00|